AMENDED AND RESTATED INTELLECTUAL PROPERTY LICENSE AND ASSIGNMENT AGREEMENTLicense and Assignment Agreement • October 17th, 2013 • Relypsa Inc • Pharmaceutical preparations • California
This Amended and Restated Intellectual Property License and Assignment Agreement (this “ Restated Agreement”) dated as of November 23, 2009 (the “Amendment Date”) is entered into by and between Relypsa, Inc., a Delaware corporation, having a place of business at 5301 Patrick Henry Drive, Santa Clara, CA 95054 (“Relypsa”) and Ilypsa, Inc., a Delaware corporation and a wholly-owned subsidiary of Amgen Inc., having a place of business at One Amgen Center Drive, Thousand Oaks, CA 91320 (“Ilypsa”).
CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS PRODUCT LICENSE AND ASSIGNMENT AGREEMENT Dated as of October 11, 2006 By and Among CYTOGEN CORPORATION (a Delaware...License and Assignment Agreement • November 9th, 2006 • Cytogen Corp • Pharmaceutical preparations • New York
LICENSE AND ASSIGNMENT AGREEMENTLicense and Assignment Agreement • March 12th, 2018 • Strongbridge Biopharma PLC • Pharmaceutical preparations • New York
ContractLicense and Assignment Agreement • March 2nd, 2021 • LAVA Therapeutics BV • Pharmaceutical preparations
[***] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
LICENSE AND ASSIGNMENT AGREEMENTLicense and Assignment Agreement • December 23rd, 2010 • Celldex Therapeutics, Inc. • In vitro & in vivo diagnostic substances • Delaware
THIS LICENSE AND ASSIGNMENT AGREEMENT (the “Agreement”) is made and entered into as of March 16, 2009 (the “Effective Date”) by and between AMGEN INC., a Delaware corporation with offices at One Amgen Center Drive, Thousand Oaks, California 91320-1799 (“Amgen”), and CELLDEX THERAPEUTICS, INC., a Delaware corporation with a place of business at 222 Cameron Drive, Suite 400, Phillipsburg, NJ 08865 (“Celldex”). Amgen and Celldex may be referred to herein individually as a “Party” and jointly as the “Parties.”
LICENSE AND ASSIGNMENT AGREEMENT THIS LICENSE and ASSIGNMENT AGREEMENT made and entered into as of the 21st day of August, 2009, by and between Lecia L. Walker and Original Source Entertainment, Inc. ("Entertainment") a Nevada corporation, with...License and Assignment Agreement • December 3rd, 2015 • Original Source Music, Inc. • Patent owners & lessors
AMENDMENT NO. 1 TO PATENT LICENSE AND ASSIGNMENT AGREEMENTLicense and Assignment Agreement • July 12th, 2007 • Pasw Inc • Services-computer programming services • California
This Amendment No. 1 to Patent License and Assignment Agreement (this “Amendment No. 1”) is entered into as of November 2, 2006 (the “Amendment Effective Date”) by and between Science Applications International Corporation, a Delaware corporation (“SAIC”), and VirnetX Inc., a Delaware corporation (“Transferee”), herein individually referred to as a “Party” and collectively referred to as the “Parties.”
LICENSE AND ASSIGNMENT AGREEMENT THIS LICENSE and ASSIGNMENT AGREEMENT made and entered into as of the 21st day of August, 2009, by and between Lecia L. Walker and Original Source Entertainment, Inc. ("Entertainment") a Nevada corporation, with...License and Assignment Agreement • October 4th, 2010 • Original Source Entertainment, Inc. • Colorado
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH LICENSE AND ASSIGNMENT AGREEMENTLicense and Assignment Agreement • August 14th, 2015 • Tapimmune Inc • Pharmaceutical preparations • Minnesota
This patent, know-how, materials license and IND assignment agreement ("Agreement") is by and between Mayo Foundation for Medical Education and Research, a Minnesota charitable corporation, located at 200 First Street SW, Rochester, Minnesota 55905-0001 ("MAYO"), and Taplmmune, Inc., a for-profit corporation, having a place of business at 2815 Eastlake Avenue, E. Suite 300, Seattle, WA 98102 ("COMPANY"), each a "Party," and collectively "Parties".
LICENSE AND ASSIGNMENT AGREEMENT between ND PARTNERS LLC and CORMEDIX, INC. LICENSE AND ASSIGNMENT AGREEMENTLicense and Assignment Agreement • March 30th, 2023 • CorMedix Inc. • Pharmaceutical preparations
This License and Assignment Agreement (hereinafter referred to as this “Agreement”), effective this 30th day of January 2008 (the “Effective Date”), is entered into by and between ND Partners LLC, a Delaware limited liability company having a place of business at One Joy Street, Boston, MA 02108 (“Licensor”), and CorMedix, Inc., a Delaware corporation having a place of business at 86 Summit Avenue, Suite 301, Summit, NJ 07901 (the “Company”).
LICENSE AND ASSIGNMENT AGREEMENTLicense and Assignment Agreement • November 19th, 2004 • Duska Therapeutics, Inc. • Biological products, (no disgnostic substances) • Pennsylvania
This License and Assignment Agreement (this “Agreement”) is made as of November 15, 1999, by and between Dr. Amir Pelleg and Dr. Edward S. Schulman (the “Inventors”) and Duska Scientific Co., a Delaware corporation (“Duska”), with its principal offices at 24 Dartmouth Lane, Haverford, PA 19041-1020.
LICENSE AND ASSIGNMENT AGREEMENTLicense and Assignment Agreement • June 6th, 2012 • Dynamic Energy Alliance Corp • Orthopedic, prosthetic & surgical appliances & supplies • Missouri
This License and Assignment Agreement (the "Agreement") is made and entered into by and among R.F.B., LLC, a Kansas limited liability company ("Licensor-Assignor"), Dynamic Energy IP, LLC, a Delaware corporation ("Licensee-Assignee"), and Gene Rickard. The "Effective Date" is the day the signed agreement is authorized by the Board of Directors of Dynamic Energy Alliance Corporation.
LICENSE AND ASSIGNMENT AGREEMENT among Velos Biopharma Holdings, LLC and VelosBio Inc. and Oncternal Therapeutics, Inc. Dated: February 6, 2018License and Assignment Agreement • April 8th, 2019 • GTX Inc /De/ • Pharmaceutical preparations • California
THIS LICENSE AND ASSIGNMENT AGREEMENT (“Agreement”), dated as of February 6, 2018 (the “Effective Date”), is entered into among Velos Biopharma Holdings, LLC., a Delaware limited liability company (“LICENSOR”), and VelosBio Inc., a Delaware corporation (“LICENSEE”) and, solely with respect to Sections 2.3, 2.6, 2.7, 3.3, 3.4, 7.1, 16.1, 16.9, 16.15 and Articles 8 and 14, Oncternal Therapeutics, Inc., a Delaware corporation (“Oncternal”). Each of LICENSOR and LICENSEE, and Oncternal solely with respect to the above-referenced Sections, may be referred to herein as a “Party,” and collectively as the “Parties”).
AMENDMENT TO LICENSE AND ASSIGNMENT AGREEMENTLicense and Assignment Agreement • May 15th, 2013 • CorMedix Inc. • Pharmaceutical preparations
This Amendment to License and Assignment Agreement (this “Amendment”) is effective as of April 11, 2013, and is between ND Partners, LLC, a Delaware limited liability company (“ND Partners”), and Cormedix, Inc., a Delaware corporation (“Cormedix”).
LICENSE AND ASSIGNMENT AGREEMENT between ND PARTNERS LLC andLicense and Assignment Agreement • December 31st, 2009 • CorMedix Inc. • Pharmaceutical preparations • New York
This License and Assignment Agreement (hereinafter referred to as this "Agreement"), effective this 30th day of January 2008 (the “Effective Date”), is entered into by and between ND Partners LLC, a Delaware limited liability company having a place of business at One Joy Street, Boston, MA 02108 (“Licensor”), and CorMedix, Inc., a Delaware corporation having a place of business at 86 Summit Avenue, Suite 301, Summit, NJ 07901 (the "Company").
Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [* * *]. A complete version of this exhibit has been filed...License and Assignment Agreement • April 1st, 2010 • SAIC, Inc. • Services-computer integrated systems design • California
This Amendment No. 1 to Patent License and Assignment Agreement (this “Amendment No. 1”) is entered into as of November 2, 2006 (the “Amendment Effective Date”) by and between Science Applications International Corporation, a Delaware corporation (“SAIC”), and VirnetX Inc., a Delaware corporation (“Transferee”), herein individually referred to as a “Party” and collectively referred to as the “Parties.”
